Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Acute respiratory distress syndrome future or investigational therapies
Introduction
Overview
Overview
Several medical therapies, including granulocyte macrophage colony stimulating factor (GM-CSF) are currently under investigation as potential treatments for ARDS.
Investigational therapies
Investigational therapies
Granulocyte macrophage colony stimulating factor (GM-CSF):
- An observational study found an association between higher levels of GM-CSF in brochoalveolar lavage (BAL) fluid and improved survival in patients with ARDS[1]
- A study of 6 patients with ARDS due to pneumonia who were administered nebulized GM-CSF demonstrated improvements in lung compliance and mortality scores; 4 of 6 patients survived to discharge[2]
- A randomized clinical trial (RCT) is currently underway to further study the potential efficacy of inhaled GM-CSF in ARDS
- An observational study of 47 patients with acute lung injury (ALI) demonstrated an association between administration of macrolide antibiotics and both early discontinuation of mechanical ventilation as well as improved survival at 180 days[3]
References
References
- ↑ Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Hudson LD; et al. (2000). “Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome”. Crit Care Med. 28 (1): 1–7. PMID 10667491.
- ↑ Herold S, Hoegner K, Vadász I, Gessler T, Wilhelm J, Mayer K; et al. (2014). “Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome”. Am J Respir Crit Care Med. 189 (5): 609–11. doi:10.1164/rccm.201311-2041LE. PMID 24579839.
- ↑ Walkey AJ, Wiener RS (2012). “Macrolide antibiotics and survival in patients with acute lung injury”. Chest. 141 (5): 1153–9. doi:10.1378/chest.11-1908. PMC 3342785. PMID 22116799.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Brian Shaller, M.D. [2]